News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

30

March

2026

Clearmind Announces Successful Completion of Treatment for 18 Participants in its Ongoing Phase I/IIa Clinical Trial
Read More
27

March

2026

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Read More
19

March

2026

Clearmind Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical...
Read More
17

March

2026

Clearmind Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Therapies
Read More
13

March

2026

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Read More
11

March

2026

Clearmind Advances Recruitment for CMND-100 Trial's 3rd Cohort at Yale, Johns Hopkins & Tel Aviv Sites Following Positive Results
Read More
10

March

2026

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Read More
4

March

2026

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Read More
9

February

2026

Clearmind Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Clinical Trial
Read More
6

February

2026

Clearmind Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic MEAI
Read More
3

February

2026

Clearmind’s Proprietary MEAI was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Treatments
Read More
14

January

2026

Clearmind Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial
Read More
31

December

2025

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
Read More
24

December

2025

Clearmind Medicine Reflects on a Transformative 2025
Read More
16

December

2025

Clearmind Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Read More